newsfilter
← Latest News
GlobeNewswire·

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to SCYNEXIS, received in Q3